Review and inventory | 2021 EBMT annual meeting research progress collection

The annual meeting of the European Society for Blood and Marrow Transplantation (EBMT) is one of the most influential international conferences in the field of blood disease treatment.
The 47th EBMT annual meeting in 2021 will be held in the form of an online virtual conference on March 14-17.
Covers major developments related to hematopoietic stem cell transplantation and cell therapy research.

[Hematology Department of Yimaitong] organized an inventory and took you to review the research progress of the EBMT annual meeting in 2021.

Click "Related Article Title" to read the relevant original text.

 01 CAR-T therapy related research progress In the case of preventive use of tocilizumab, the anti-CD19 chimeric antigen receptor (CAR)-T cells produced by automated cell manufacturing platforms will still cause severe cytokine release in some children Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS).

A study modified the CAR-T application program to adapt the initial dose of CAR-T to the leukemia burden of children, and divided infusions for high-risk children.

For details, please click: 2021 EBMT | Anti-CD19 CAR-T therapy for children with R/R ALL: Fractional infusion can improve safety while maintaining the effectiveness of treatment.
The high expression of CD123 in leukemia stem cells in acute myeloid leukemia (AML), It is a potential new target for chimeric antigen receptor (CAR) cell therapy.

The Italian research team explored the anti-tumor activity of CAR.
CD123-NK cells in vivo and in vitro.For details, please click: 2021 EBMT | CAR.
CD123-NK cells are expected to bring new treatment strategies for CD123-positive children with AML.
The ZUMA-5 study is an autologous anti-CD19 chimeric antigen receptor (CAR)-T cell therapy: Axicabtagene ciloleucel (Axi-cel) A phase 2, multi-center, single-arm study for the treatment of patients with relapsed and refractory (R/R) indolent non-Hodgkin's lymphoma (iNHL).

For details, please click: 2021 EBMTZUMA-5 study: Axi-cel treatment of R/R iNHL, long-lasting benefits, safe and manageable OUTREACH study aims to observe the treatment of hospitalization in non-university medical centers (NMCs) lisocabtagene maraleucel (liso-cel) And the effectiveness and safety of patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) in outpatient clinics.

For details, please click: 2021 EBMT｜CAR-T therapy liso-cel has similar effects in inpatient and outpatient patients: preliminary results of the OUTREACH study The chimeric antigen receptor (CAR)-T cell therapy ciltacabtagene autoleucel was announced at the EBMT annual meeting (Cilta-cel) The results of the Phase Ib/II CARTITUDE-1 study on the treatment of relapsed and refractory multiple myeloma (RRMM).

For details, please click: 2021 EBMT | CARTITUDE-1 Study: CAR-T therapy cilta-cel treatment of RRMM brings deep relief and controllable safety.
Autologous anti-CD19 chimeric antigen receptor (CAR) was announced at this EBMT annual meeting- Interim analysis results of ZUMA-12 study of T-cell therapy Axi-cel as the first-line treatment of patients with large B-cell lymphoma (LBCL). For details, please click: 2021 EBMT｜Axi-Cel as the first-line treatment of high-risk LBCL patients Phase II study: ZUMA-12 Interim Analysis The ZUMA-2 study is a phase II study designed to evaluate KTE-X19 (an autologous anti-CD19) Chimeric antigen receptor [CAR]-T cell therapy) has developed into relapsed/refractory (R/R) mantle cell lymph after previous 1-5 treatments (including Bruton tyrosine kinase inhibitor [BTKi]) Efficacy in patients with tumor (MCL).

The results of all patients who were followed up for more than 1 year in the ZUMA-2 study were announced at this EBMT annual meeting.

For details, please click: 2021 EBMTZUMA-2 Study: KTE-X19 in the treatment of R/R MCL, with long-lasting benefits and multi-point effectiveness.
Axicabtagen Ciloleucel (Axi-cel) is approved in Europe for the treatment of relapsed and refractory large B-cell lymph Adult patients with tumor (R/R LBCL), primary mediastinal B-cell lymphoma (PMBCL), and transforming follicular lymphoma (tFL).

M.
Kwon et al.
analyzed the results of real-world studies on the use of Axi-cel to treat patients in Spain.

For details, please click: 2021 EBMT｜Axi-cel speaks with real-world data, and treats R/R LBCL ORR up to 78%.
02 Pre-transplant pre-treatment program related research progress.
Carmustine (BCNU)-based pre-treatment program is autologous Hematopoietic stem cell transplantation (aHCT) is a standard protocol for the treatment of relapsed and refractory non-Hodgkin's lymphoma (R/R NHL).

Due to the shortage of carmustine in Canada, the price of carmustine has risen sharply.
In May 2015, the Mason-Rosemont Hospital Research Center of the University of Montreal decided to use bendamustine (Benda) instead of aHCT pretreatment program In carmustine.

As a quality control, the center compared the efficacy results of the two pretreatment programs.

For more details, please click: 2021 EBMT | Bendamustine pretreatment program can improve the prognosis of transplanted R/R NHL patients.
This EBMT annual meeting announced a number of rucotinib pretreatment programs on myelofibrosis (MF ) The results of the study on the prognosis of patients with allogeneic hematopoietic stem cell transplantation (alloHCT).

For more details, please click: 2021 EBMT | The effect of rucotinib pretreatment regimen on the prognosis of allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis A retrospective study by F.
Sora et al.
compared cetepa + busulfan + fludarabine (TBF) pretreatment program and other programs affect AML patients.

For details, please click: 2021 EBMT | TBF program can improve disease-free survival of patients with AML in complete remission.
03 Chinese experts related research progress.
With the advancement and innovation of medical technology, China is also playing an increasingly important role in the world medical field.
More and more Chinese experts are showing their style at international conferences.
A total of 2 Oral and 10 Poster are shortlisted for the 2021 EBMT Annual Conference.

For more details, please poke: 2021 EBMT | China Research Report First Look, 10 Highlights of Poster Highlights.
Professor Feng Sizhou's team from the Hematology Hospital of the Chinese Academy of Medical Sciences conducted the diagnosis and treatment stratification of aggressive mycosis (IFD) in patients with hematological malignancies in this hospital Conducted a real-world study.

For details, please poke: 2021 EBMT Voice of China | Hospital of Hematology, Chinese Academy of Medical Sciences: Real-world situation of IFD diagnosis and treatment stratification for patients with hematological malignancies.
Professor Lu Daopei's team at Lu Daopei Hospital conducted a retrospective study to compare anti-T Lymphocyte globulin (ATLG) and rabbit antithymocyte globulin (rATG) anti-CD19 chimeric antigen receptor (CAR)-T cell therapy for the treatment of relapsed/refractory (R/R) and high-risk B cell acute bridging transplantation The prognosis of patients with lymphocytic leukemia (B-ALL). For more details, please click: 2021 EBMT Voice of China | ATLG vs rATG Comparison of the prognosis of CAR-T bridge transplantation R/R and high-risk B-ALL patients 04 Other research progress High-risk acute myeloid leukemia (HR-AML) and elderly AML Patients have cytogenetic factors with a poor prognosis and a high probability of comorbidities.

These patients do not respond well to induction therapy, and the prognosis is worse than that of patients with relapsed and refractory (R/R) AML.

A study explored the efficacy and safety of Venecla combined with hypomethylation drugs (HMA) in the treatment of newly-treated AML and R/R AML, and also evaluated the role of this regimen in bridging transplantation.

For more details, please click: 2021 EBMT | Vinekal combined with hypomethylation drugs to treat high-risk AML is safe and effective.
It can effectively bridge transplantation.
Autologous hematopoietic stem cell transplantation is the standard treatment for multiple myeloma (MM), but patients will still be treated after transplantation.
Relapse requires additional treatment.

The Phase III IKEMA study (NCT03275285) confirmed that the Kd regimen (carfilzomib combined with dexamethasone) combined with Isatuximab (Isa-Kd regimen) can benefit patients with relapsed and refractory MM.
The study's subgroup analysis and exploration The efficacy and safety of this combination scheme in MM patients who have previously received transplantation are discussed.

For details, please click: 2021 EBMT | IKEMA study subgroup analysis: Kd regimen combined with Isatuximab will benefit MM patients after transplantation.
Rucotinib is an oral selective JAK1/JAK2 inhibitor that inhibits JAK-STAT pathway The proliferation and differentiation of inflammatory cells is currently one of the most effective drugs for the treatment of glucocorticoid resistance (SR) graft versus host disease (GVHD).

For details, please poke: 2021 EBMT | Rucotinib GVHD treatment journey, REACH3 research renewal The long-term follow-up of multiple gene therapy Betibeglogene Autotemcel (beti-cel) in the treatment of transfusion-dependent thalassemia (TDT) will be announced at this EBMT annual meeting Research result.

For details, please click: 2021 EBMT | Gene Therapy Beti-cel Treatment of Transfusion-dependent Thalassemia Long-term Follow-up Results A study aimed to clarify that cyclophosphamide (PTCY) is used in haploid peripheral blood stem cell transplantation (Haplo-PBSCT) Whether combined anti-thymocyte globulin (ATG) therapy is better than PTCY single agent.

For details, please click: 2021 EBMT｜Adding ATG to cyclophosphamide treatment after Haplo-PBSCT can reduce the risk of cGVHD Jean Roy et al.
hypothesized that bortezomib (BTZ) maintenance treatment after allogeneic hematopoietic stem cell transplantation (allo-HCT) can be used Reduce the disease recurrence rate and the incidence of chronic graft-versus-host disease (cGVHD) in high-risk, young multiple myeloma (MM) patients, and conduct clinical studies to try to determine the effect of bone marrow measurable residual disease (MRD) on future disease progression influences.

For details, please click: 2021 EBMT | Allo-HCT followed by bortezomib treatment of MM can significantly reduce the incidence of moderate/severe cGVHD.
Nicolaus Kröger and others in Germany conducted a study that compared autologous hematopoietic stem cell transplantation (ASCT) sequential allo- HSCT (auto-allo TSCT) followed by maintenance therapy, followed by ASCT (auto-auto TSCT) followed by maintenance therapy in patients with newly diagnosed multiple myeloma (MM).

For details, please click: 2021 EBMT | ASCT sequential allo-HSCT followed by maintenance treatment can improve the efficacy of MM patients? Poke "read the original text" and we will make progress together